Identification of CD49a+ CD8+ resident memory T cells in vitiligo‐like lesions associated with nivolumab treatment for melanoma

Identification of CD49a+ CD8+ resident memory T cells in vitiligo‐like lesions associated with nivolumab treatment for melanoma:

Abstract

Immune checkpoint inhibitor (ICI) has brought major therapeutic advances in melanoma care, but ICI can cause unique side effects, often termed immune‐related adverse events (irAEs), such as skin rash, vitiligo, colitis, and pneumonitis. Several recent studies revealed a correlation between occurrence of vitiligo‐like lesions and clinical responses in advanced melanoma patients during ICI treatment.